Cachet Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 1.78 M
- Company Age 46 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.90 Cr
- Satisfied Charges ₹ 108.50 Cr
- Revenue Growth -6.19%
- Profit Growth 23.27%
- Ebitda 4.19%
- Net Worth 21.59%
- Total Assets 5.27%
About Cachet Pharmaceuticals
Cachet Pharmaceuticals Private Limited (CPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 April 1978 and has a history of 46 years and ten months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 1.78 M.
The company currently has active open charges totaling ₹4.90 Cr. The company has closed loans amounting to ₹108.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Satish Singh, Arunkumar Deshmukh, Anuja Sinha, and One other member serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230BR1978PTC001328
- Company No.
001328
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 1978
- Date of AGM
20 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
What products or services does Cachet Pharmaceuticals Private Limited offer?
Cachet Pharmaceuticals Private Limited offers a wide range of products and services, including Veterinary Medicines, Veterinary Pharmaceuticals, Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet, Industrial Chemicals & Supplies, Chemical Compound, Brain & Nervous System Drugs, Antimigraine Drug, Chemical Reagents & Catalysts, Iodine Compounds.
Who are the key members and board of directors at Cachet Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Satish Singh ![]() | Managing Director | 16-Jun-2001 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Arunkumar Deshmukh ![]() | Director | 15-Jun-2015 | Current |
Anuja Sinha ![]() | Director | 16-Nov-2015 | Current |
Premlata Singh ![]() | Director | 30-May-2019 | Current |
Financial Performance of Cachet Pharmaceuticals.
Cachet Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.19% decrease. The company also saw a substantial improvement in profitability, with a 23.27% increase in profit. The company's net worth Soared by an impressive increase of 21.59%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Cachet Pharmaceuticals?
In 2023, Cachet Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹49.00 M
₹1,084.95 M
Charges Breakdown by Lending Institutions
- Others : 4.90 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
09 Feb 2024 | Others | ₹4.90 Cr | Open |
08 Aug 2023 | Others | ₹4.50 Cr | Satisfied |
26 Dec 2019 | Others | ₹4.50 Cr | Satisfied |
11 Jan 2017 | Others | ₹4.00 M | Satisfied |
04 Nov 2016 | Others | ₹15.00 Cr | Satisfied |
How Many Employees Work at Cachet Pharmaceuticals?
Cachet Pharmaceuticals has a workforce of 1428 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Cachet Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cachet Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.